RESUMO
Fifty five patients with hormone-resistant prostate cancer were included in this retrospective controlled study. Chemotherapy with intravenous docetaxel (75 mg/m2 for 21 days) was performed in 30 patients, 25 patients received metronomic oral therapy with cyclophosphamide (50 mg/day). The central objective of this study was the comparison of overall survival in these groups. Pain management effectiveness, quality of life and PSA level were also compared. In docetaxel group the median overall survival was 15.9 +/- 1.7 months, in cyclophosphamide group 15.4 +/- 2.2 months (p = 0.5). Frequency of PSA level decrease was 76.7% and 44%, PSA response to therapy was observed in 46.7% and 12% of patients (p = 0.04 and p = 0.02). In docetaxel group pain reduction was achieved in 42.9% and in cyclophosphamide group in 31.3% of cases (p = 0.60). Grade III-IV hematological toxicity was observed only in docetaxel group (33% of patients), in 16.7% of patients receiving docetaxel the therapy had to be ceased due to adverse effect. Quality of live was improved in 26.7% of patients receiving docetaxel and in 16% of patients receiving cyclophosphamide.
